{
    "clinical_study": {
        "@rank": "70335", 
        "acronym": "BOOST\u00ae", 
        "arm_group": [
            {
                "arm_group_label": "IDegAsp BID (twice daily) simple titration", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp BID (twice daily) stepwise titration", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\n\n      The aim of the trial is to compare the efficacy and safety of two different titration\n      algorithms for insulin degludec/insulin aspart (IDeg/IAsp)  in subjects with type 2 diabetes\n      mellitus previously treated with insulin glargine."
        }, 
        "brief_title": "Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2\n             (randomisation)\n\n          -  Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs\n             (OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase\n             inhibitor). All antidiabetic treatments should have been ongoing for at least 12\n             weeks prior to Visit 2 (randomisation) and doses should have been stable in this\n             period of time\n\n          -  Glycosylated haemoglobin (HbA1c) 7.0-10.0% (both inclusive) by central laboratory\n             analysis\n\n          -  Body mass index (BMI) below or equal to 40 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or\n             thiazolidinediones (TZDs) both within the last 12 weeks prior to Visit 2\n             (randomisation)\n\n          -  Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial\n             infarction; unstable angina pectoris; or coronary arterial bypass graft or\n             angioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)\n\n          -  Uncontrolled or untreated severe hypertension defined as systolic blood pressure\n             above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg\n\n          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12\n             months) or hypoglycaemic unawareness as judged by the investigator\n\n          -  Life-threatening disease (e.g. cancer)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "272", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680341", 
            "org_study_id": "NN5401-3941", 
            "secondary_id": [
                "2012-000373-23", 
                "U1111-1127-4114"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "IDegAsp BID (twice daily) simple titration", 
                "description": "Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.", 
                "intervention_name": "IDegAsp", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp BID (twice daily) stepwise titration", 
                "description": "Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.", 
                "intervention_name": "IDegAsp", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Glargine", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 7, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Goodyear", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85395"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85020"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92111"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spring Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91978"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kissimmee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34741"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33324"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33709"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwanee", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30024"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crystal Lake", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60012"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Avon", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46123"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46254"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slidell", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70461-4231"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waltham", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02453"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buckley", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49620"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashua", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03063"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08648"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toms River", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08755-8050"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12206"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29407"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572-4610"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75251"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olympia", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98502"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kenosha", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53142-7884"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Algiers", 
                        "country": "Algeria", 
                        "zip": "16000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Ingbert", 
                        "country": "Germany", 
                        "zip": "66386"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kota Bharu, Kelantan", 
                        "country": "Malaysia", 
                        "zip": "16150"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "34740"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Algeria", 
                "Germany", 
                "Malaysia", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Comparing the Efficacy and Safety of Two Different Titration Algorithms for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST\u00ae: SIMPLE vs. STEPWISE)", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Algeria: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Malaysia: Medical Research Ethics Committee", 
                "Turkey: Ministry of Health Drug and Pharmaceutical Department", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c (glycosylated haemoglobin) (%)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, Week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680341"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, Week 26"
            }, 
            {
                "measure": "Proportion of subjects with HbA1c below 7.0%", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Proportion of subjects with HbA1c below 7.0% without confirmed hypoglycaemic episodes during the last 12 weeks of treatment or within 7 days from last randomised treatment including only subjects exposed for at least 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Incidence of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-28"
            }, 
            {
                "measure": "Number of treatment emergent confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-27"
            }, 
            {
                "measure": "Number of treatment emergent confirmed hypoglycaemic episodes in the maintenance period", 
                "safety_issue": "No", 
                "time_frame": "From week 16 to end of trial including follow-up (week 27)"
            }, 
            {
                "measure": "Number of treatment emergent nocturnal (00:01-05:59) confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-27"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}